Dr. Hurtado-Lorenzo is a translational scientist leader with previous proven success directing multidisciplinary teams focused on drug discovery and development for neurological diseases and rare diseases in the biotech and pharmaceutical industry (Wyeth, Pfizer, Proteostasis Therapeutics) from discovery to early clinical development. These efforts have resulted in the identification of candidate drugs currently evaluated in clinical trials.
He obtained his Ph.D. in Molecular Medicine from the University of Manchester in the UK, where he pioneered work in the field of viral gene therapy for neurodegenerative diseases. He completed his postdoctoral work at Harvard Medical School, Massachusetts General Hospital and Columbia University, where he conducted groundbreaking research focused on molecular mechanisms of autophagy and other protein degradation pathways and their role in health and disease. His research has been published in books high impact factor publications like Nature Cell Biology and Nature Communications.